Category: Our Science
From Paper to Pill
There is opportunity to develop new and potentially improved molecules that block HIF-2α to further improve outcomes.
Addressing Adenosine: Immunotherapy in the Tumor Microenvironment
Targeting the adenosine axis – components that contribute to the production of adenosine and its subsequent impact – is a promising option.
The Fc-silent Treatment: Pursuing a Known Target in a New Way
We were among the first to take a different approach and pursue an Fc-silent anti-TIGIT antibody based on our own scientific understanding of how this biological pathway works.
Investigating Combination Therapies to Treat Cancer
Learn how cancer biology is guiding the study of potential, new combination medicines to treat specific types of cancer.
Taking the Brakes Off the Immune System: Exploring Immunotherapy Combinations
Our immune system is made up of different types of cells that search for and destroy foreign invaders. These adversaries can include bacteria and viruses, as well as abnormal versions of our own cells, like those in cancerous tumors.
